# Loss-of-function of *MFGE8* and protection against coronary atherosclerosis

Sanni E. Ruotsalainen<sup>1</sup>, Ida Surakka<sup>2</sup>, Nina Mars<sup>1</sup>, Juha Karjalainen<sup>3</sup>, Mitja Kurki<sup>3</sup>, Masahiro Kanai<sup>3-5</sup>, Kristi Krebs<sup>6</sup>, Pashupati P. Mishra<sup>7-9</sup>, Binisha H. Mishra<sup>7-9</sup>, Juha Sinisalo<sup>10</sup>, Priit Palta<sup>1,6</sup>, Terho Lehtimäki<sup>7-9</sup>, Olli Raitakari<sup>11-13</sup>, *Estonian Biobank research team*, Lili Milani<sup>6</sup>, *The Biobank Japan Project*<sup>14</sup>, Yukinori Okada<sup>5,15</sup>, *FinnGen*, Aarno Palotie<sup>1,3</sup>, Elisabeth Widen<sup>1</sup>, Mark J. Daly<sup>1,3,4</sup>, Samuli Ripatti<sup>1,3,16</sup>\*

- 1) Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- 2) Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- 3) The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- 4) Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 5) Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan
- 6) Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 7) Department of Clinical Chemistry, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 8) Finnish Cardiovascular Research Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 9) Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
- 10) Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland
- 11) Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
- 12) Centre for Population Health Research, University of Turku, Turku University Hospital, Turku, Finland
- 13) Department of Clinical Physiology and Nuclear Medicine, University of Turku, Turku, Finland
- 14) Institute of Medical Science, The University of Tokyo
- 15) Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 16) Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland

\*Corresponding author

Tel: +358 40 567 0826

E-mail: samuli.ripatti@helsinki.fi

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Cardiovascular diseases are the leading cause of premature death and disability worldwide, with both genetic and environmental determinants. While genome-wide association studies have identified multiple genetic loci associated with cardiovascular diseases, exact genes driving these associations remain mostly uncovered. Due to Finland's population history, many deleterious and high-impact variants are enriched in the Finnish population giving a possibility to find genetic associations for protein-truncating variants that likely tie the association to a gene and that would not be detected elsewhere. In FinnGen, a large Finnish biobank study, we identified an inframe insertion rs534125149 in MFGE8 to have protective effect against coronary atherosclerosis (OR = 0.75, p =  $2.63 \times 10^{-16}$ ) and related endpoints. This variant is highly enriched in Finland (70-fold compared to Non-Finnish Europeans) with allele frequency of 3% in Finland. The protective association was replicated in meta-analysis of biobanks of Japan and Estonian (OR = 0.75, p =  $5.41 \times 10^{-7}$ ). Additionally, we identified a splice acceptor variant rs201988637 in MFGE8, independent of the rs534125149 and similarly protective in relation to coronary atherosclerosis (OR = 0.72, p =  $7.94 \times 10^{-1}$ <sup>06</sup>) and related endpoints, with no significant risk-increasing associations. The protein-truncating variant was also associated with lower pulse pressure, pointing towards a function of MFGE8 in arterial stiffness and aging also in humans in addition to previous evidence in mice. In conclusion, our results show that inhibiting the production of lactadherin could lower the risk for coronary heart disease substantially.

**Keywords:** coronary atherosclerosis, myocardial infarction, loss-of-function, MFGE8

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Introduction Cardiovascular disease (CVD) is the leading cause of premature death and disability worldwide, with both genetic and environmental determinants<sup>1, 2</sup>. The most common cardiovascular disease is coronary heart disease (CHD), including coronary atherosclerosis and myocardial infarction, among others. While genome-wide association studies (GWAS) have identified multiple genetic loci associated with cardiovascular diseases, exact genes driving these associations remain mostly uncovered<sup>3</sup>. Due to Finland's population history, many deleterious and high-impact variants are enriched in the Finnish population giving a possibility to find genetic associations that would not be detected elsewhere<sup>4</sup>. Many studies have reported high-impact loss-of-function (LoF) variants associated with risk factors for CVD, such as blood lipid levels, thus impacting on the CVD risk remarkably. For example, high-impact LoF variants in genes LPA4, PCSK95, APOC36 and ANGPTL4 7 have been shown to be associated with Lipoprotein(a), LDL-cholesterol (LDL-C) or triglyceride levels and lowering the CVD risk. Besides blood lipids, other risk factors for CVD include hypertension, smoking and the metabolic syndrome cluster components. The mechanism that links these risk factors to atherogenesis, however, remains incompletely elucidated. Many, if not all, of these risk factors, however, also participate in the activation of inflammatory pathways, and inflammation in turn can alter the function of artery wall cells in a manner that drives atherosclerosis<sup>8</sup>. Using data from a sizeable Finnish biobank study FinnGen (n = 260 405), we identified an inframe insertion rs534125149 in MFGE8 to protect against coronary atherosclerosis and related endpoints, such as myocardial infarction (MI). This variant is highly enriched in Finland, 70- fold compared to

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Non-Finnish Europeans (NFE) in the gnomAD genome reference database<sup>9</sup> with AF of 3% in Finland. This association was also replicated in BioBank Japan (BBJ) and Estonian Biobank (EstBB). We also identified a splice acceptor variant rs201988637 in the same gene, which is also protective against coronary atherosclerosis-related endpoints, indicating that rs534125149 act as a loss-of-function variant in MFGE8. Associations of functional variants in MFGE8 were specific to coronary atherosclerosis-related endpoints, and they did not significantly (p <  $1.75 \times 10^{-5}$ ) increase risk for any other disease, highlighting MFGE8 as a potential drug target candidate. Material and methods Study cohort and data We studied total of 2 861 disease endpoints in Finnish biobank study FinnGen (n = 260 405) (**Table** 1). FinnGen (https://www.finngen.fi/en) is a large biobank study that aims to genotype 500 000 Finns and combine this data with longitudinal registry data, including national hospital discharge, death, and medication reimbursement registries, using unique national personal identification numbers. FinnGen includes prospective epidemiological and disease-based cohorts as well as hospital biobank samples. Definition of disease endpoints All the 2 861 disease-endpoint analysed in FinnGen have been defined based on registry linkage to national hospital discharge, death, and medication reimbursement registries. Diagnoses are based on International Classification of Diseases (ICD) codes and have been harmonized over ICD codes 8,9 and 10. More detailed lists of the ICD codes used for the disease-endpoints myocardial infarction and coronary atherosclerosis, which are discussed more in this study, are in Supplementary Material. A

73 complete list of endpoints analysed, and their definitions is available at 74 <a href="https://www.finngen.fi/en/researchers/clinical-endpoints">https://www.finngen.fi/en/researchers/clinical-endpoints</a>.

**Table 1:** Basic characteristics of the study cohort.

	All	Females	Males
N (%)	260 405	147 061 (56.47 %)	113 344 (43.53 %)
Age (mean (sd))	53.15 (17.55)	51.84 (17.71)	54.85 (17.19)
BMI (mean (sd)) <sup>a</sup>	27.29 (5.36)	27.21 (5.83)	27.38 (4.76)
Statin use (N (%))	86 466 (33.2 %)	40 422 (27.48 %)	46 044 (40.62 %)
Hypertension (N (%))	68 005 (26.11 %)	33 420 (22.72 %)	34 585 (30.51 %)
Smoking (N (%)) b	1 733 (1.07 %)	901 (0.96 %)	832 (1.22 %)
Coronary atherosclerosis	28 598 (11.38 %)	9 252 (6.87 %)	19 346 (17.86 %)
Myocardial infarction	14 305 (6.04 %)	3 958 (2.87 %)	10 347 (10.42 %)

<sup>&</sup>lt;sup>a</sup>BMI is available only from 178 966 individuals

# Genotyping and imputation

FinnGen samples were genotyped with multiple Illumina and Affymetrix arrays (Thermo Fisher Scientific, Santa Clara, CA, USA). Genotype calls were made with GenCall and zCall algorithms for Illumina and AxiomGT1 algorithm for Affymetrix chip genotyping data batchwise. Genotyping data produced with previous chip platforms were lifted over to build version 38 (GRCh38/hg38) following the protocol described here: dx.doi.org/10.17504/protocols.io.nqtddwn. Samples with sex discrepancies, high genotype missingness (>5%), excess heterozygosity (±4SD) and non-Finnish ancestry were removed. Variants with high missingness (>2%), deviation from Hardy–Weinberg equilibrium (P < 1×10-6) and low minor allele count (MAC < 3) were removed.

<sup>&</sup>lt;sup>b</sup> Smoking information is available only from 98 654 individuals

Pre-phasing 2.3.5 of genotyped data performed with Eagle was (https://data.broadinstitute.org/alkesgroup/Eagle/) with the default parameters, except the number of conditioning haplotypes was set to 20,000. Imputation of the genotypes was carried out by using the population-specific Sequencing Initiative Suomi (SISu) v3 imputation reference panel with Beagle 4.1 (version 08Jun17.d8b, https://faculty.washington.edu/browning/beagle/b4\_1.html) as described in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. SISu v3 imputation reference panel was developed using the high-coverage (25–30x) whole-genome sequencing data generated at the Broad Institute of MIT and Harvard and at the McDonnell Genome Institute at Washington University, USA; and jointly processed at the Broad Institute. Variant callset was produced with Genomic Analysis Toolkit (GATK) HaplotypeCaller algorithm by following GATK best practices for variant calling. Genotype-, sample- and variant-wise quality control was applied in an iterative manner by using the Hail framework v0.2. The resulting high-quality WGS data for 3 775 individuals were phased with Eagle 2.3.5 as described above. As a post-imputation quality control, variants with INFO score < 0.7 were excluded.

# Association testing

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

A total of 260 405 samples from FinnGen Data Freeze 6 with 2 861 disease endpoints were analyzed using Scalable and Accurate Implementation of Generalized mixed model (SAIGE), which uses saddlepoint approximation (SPA) to calibrate unbalanced case-control ratios<sup>10</sup>. Models were adjusted for age, sex, genotyping batch and first ten principal components. All variants reaching genome-wide significance p-value threshold of  $5\times10^{-8}$  are considered as genome-wide significant (GWS), and all disease- endpoints reaching multiple testing corrected (for the number of endpoints tested = 2 861) p-value threshold of 0.05/2 861 =  $1.75\times10^{-5}$  were considered as phenome-wide significant (PWS).

Independent GWS loci for atherosclerosis were determined as adding ±0.5Mb around each variant that reach the genome-wide significance threshold, overlapping regions were merged. The NHGRI-EBI GWAS Catalog<sup>11</sup> was used for assessing the novelty of the independent loci with any CVDrelated endpoint or traditional risk factor for CVD, such as blood lipids, BMI and blood pressure. All novel loci for CVD were fine-mapped using FINEMAP<sup>12</sup> to determine the credible sets in each signal. In Corogene<sup>13</sup> ( $n = 5\,300$ ), a sub-cohort of FinnGen where participants have been collected as patients with coronary artery disease CAD) and other related heart diseases, we tested the association of rs534125149 with sub-types of coronary heart disease (acute coronary syndrome, stable coronary heart disease (CHD) and other heart attacks). The acute coronary syndrome was further divided into unstable Angina pectoris, non-ST segment elevation myocardial infarction (NSTEMI) and STsegment elevation myocardial infarction (STEMI). Associations were tested by calculating risk ratios (RR) for carriers vs. non-carriers of rs534125149 using non-CHD group always as controls and excluding the other tested groups from the analysis. P-values were calculated using  $\chi^2$ - test, and pvalues < 0.05 were considered significant.

# Survival analysis

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132133134

135

136

137

138

139

140

Survival analysis for coronary atherosclerosis and myocardial was performed using GATE<sup>14</sup>, which accounts for both population structure and sample relatedness and controls type I error rates even for phenotypes with extremely heavy censoring. GATE transforms the likelihood of a multivariate Gaussian frailty model to a modified Poisson generalized linear mixed model (GLMM<sup>15, 16</sup>), and to obtain well-calibrated p-values for heavily censored phenotypes, GATE uses the SPA to estimate the null distribution of the score statistic. For coronary atherosclerosis and myocardial infarction, survival time from birth to first diagnose was analyzed for both rs534125149 and rs201988637. Models were

142

143

144145146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

adjusted for age, sex, genotyping batch and first ten principal components, similarly to original GWAS analyses. Replication and biomarker analyses We tested the association of the two MFGE8 variants (rs534125149 and rs201988637) with quantitative measurements of cardiometabolic relevance or known risk factors for CVD in two subcohorts of FinnGen, the population-based national FINRISK study<sup>17</sup> (n = 26 717) and GeneRISK<sup>18</sup> (n = 7 239). The associations were tested across 66 quantitative measurements of cardiometabolic relevance in FINRISK, and for 158 sub-lipid species in GeneRISK. In Young Finns Study (YFS)<sup>19</sup> cohort (n = 1.934), we tested the association of the two variants with three measurements of arterial relevance (carotid artery distensibility, pulse wave velocity and pulse pressure). In addition to Finnish cohorts described above, we tested the association of the two variants in Estonian Biobank data (EstBB)<sup>20,21</sup>, BioBank Japan (BBJ) <sup>22,23</sup> and UK Biobank (UKBB)<sup>24</sup>. In EstBB (n = 51 388-137722) we tested the associations of both variants with body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP) and pulse pressure (PP), in BBJ in we tested the association of rs534125149 with 17 known quantitative risk factors for CVD and lastly, in the UKBB we tested the association of rs201988637 with 79 measurements of cardiometabolic relevance. In all of these biomarker analyses, a linear regression model adjusted for age and sex was used and for all quantitative risk factors rank-based inverse normal transformation was applied prior to analysis. Bonferroni corrected p-value threshold for the number of phenotypes tested was used to assess the significance of resulting associations in each cohort. For biomarkers that showed significant association in any of the cohorts, we performed a metaanalysis across all cohorts the measurement was available. Meta-analysis was performed using

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187


188

189

190

inverse-variance weighted fixed-effects meta-analysis method<sup>25, 26</sup>. Bonferroni corrected p-value for number of traits tested (n = 2) was used to assess the significance of resulting associations in metaanalysis. Identifying causal variants We used FINEMAP<sup>12</sup> on the GWAS summary statistics to identify causal variants underlying the associations for MI (strict definition, i.e., only primary diagnoses accepted) and coronary atherosclerosis. FINEMAP analyses were restricted to a ±1.5Mb region around the rs534125149. We assessed variants in the top 95% credible sets, i.e., the sets of variants encompassing at least 95% of the probability of being causal (causal probability) within each causal signal in the genomic region. Credible sets were filtered if minimum linkage disequilibrium (LD, r<sup>2</sup>) between the variants in the credible set was < 0.1, i.e., not clearly representing one signal. Results GWAS results for Coronary Atherosclerosis We identified a total of 2 302 variants associated (GWS, p  $< 5 \times 10^{-8}$ ) with coronary atherosclerosis (detailed description of the definition of the endpoint is in Supplementary Material). These variants were located in 38 distinct genetic loci (a minimum of 0.5 Mb distance from each other; **Figure 1**). Out of the 38 GWS loci, four (within or near genes MFGE8, TMEM200A, PRG3 and FHL1) were novel for any CVD-related endpoints or risk factor for CVD compared to the GWAS Catalog<sup>11</sup> [https://www.ebi.ac.uk/gwas/] (Supplementary Table 1). Lead variants in these novel loci and their characteristics are listed in **Table 2** and locus zoom plots for each of the loci are in **Supplementary** Figure 1.

Among the three novel loci for coronary atherosclerosis, the locus near MFGE8 had the strongest association (p-value =  $2.63 \times 10^{-16}$  for top variant rs534125149). The lead variant is an inframe insertion located in the sixth exon in the MFGE8 gene (**Supplementary Figure 2**) and it is highly enriched in the Finnish population compared to NFSEEs (Non-Finnish, Estonian or Swedish Europeans). Interestingly, MFGE8 is mainly expressed in coronary and tibial arteries according to data from GTEx v8 (**Supplementary Figure 3**).



**Figure 1:** GWAS results for coronary atherosclerosis in FinnGen. Total number of independent genome-wide significant associations (GWS;  $p < 5 \times 10^{-8}$ ) is 38, the lead variant in each marked with diamonds. Four novel associations for CVD- related phenotypes are highlighted with  $\pm 750$  Mb around the lead variant in the region as red and the lead variant marked with red diamond.

In addition to *MFGE8*, we identified three additional novel loci to be associated with coronary atherosclerosis, *TMT200A*, *PRG3* and *FHL1* being the nearest genes of the lead variants. *TMT200A* and *PRG3* loci had one non-coding low-frequency variant reaching the genome-wide significance threshold, and *FHL1* had 11. All variants in the credible sets of all these associations were either

intergenic or intronic variants and had no reported significant GWAS associations with any trait in the GWAS Catalog or significant eQTL associations in GTEx. The one variant (rs118042209) in the credible set of *TMEM200A* locus was associated with multiple coronary atherosclerosis related endpoints in FinnGen, including coronary atherosclerosis, ischemic heart disease and angina pectoris, whereas the lead variant in the *PRG3* locus was associated with several cardiomyopathy related endpoints. All variants in the credible set of *FHL1* were associated with multiple coronary atherosclerosis and related endpoints in FinnGen, including angina pectoris and ischemic heart disease. *TMEM200A* have been reported to be associated with ten traits (including height and trauma exposure) and *PRG3* with two traits (eosinophil count and eosinophil percentage of white cells) in the GWAS Catalog. *FHL1* gene had no reported associations in GWAS Catalog.

**Table 2:** Lead variants in novel loci associated with coronary atherosclerosis.

Lead variant chrom:pos:ref_alt (rsid)	Most severe consequence	Nearest gene	FIN enrichment (NFE)	AF	OR (P-value)	Info	# cs (Post- pr)	# coding in cs(s)
chr15:88901702:C_CTGT (rs534125149)	Inframe insertion	MFGE8	70.59	0.029	0.75 (2.60×10 <sup>-16</sup> )	0.99	2 (0.705)	1
chr6:130483492:A_G (rs118042209)	Intergenic variant	TMEM200A	0.87	0.010	0.7 (1.90×10 <sup>-9</sup> )	0.91	1 (0.904)	0
chr11:57380633:A:G (rs764568652)	Intron variant	PRG3	_ a	0.0003	7.72 (4.10×10 <sup>-8</sup> )	0.89	1 (0.583)	0
chrX:136194941:C_G (rs5974585)	Intron variant	FHL1	1.25	0.49	0.95 (2.55×10-08)	0.99	1 (0.692)	0


<sup>&</sup>lt;sup>a</sup> Variant not present in NFE in gnomAD

In the PRG3 locus the lead variant is 40.9 kb away from a variant (chr11:57340143:G:A (rs11603691), the p-value for coronary atherosclerosis risk = 0.0269) which has previously been reported to be associated with HDL- cholesterol (HDL-C). However, our association is independent

of the previously reported variant rs11603691 (p-value for rs764568652 in a conditional analysis = 4.36×10<sup>-08</sup>)

Replication and phenome-wide association results for rs534125149

We observed a highly protective association for the Finnish enriched inframe insertion rs534125149 in the *MFGE8* gene and coronary atherosclerosis related endpoints, including coronary atherosclerosis (OR = 0.72 [0.63-0.83], p = 7.94×10<sup>-06</sup>) and myocardial infarction (MI) (OR = 0.69 [0.58-0.83], p = 9.62×10<sup>-05</sup>) (**Figure 2**). In total, this variant had PWS significant protective effect on 14 disease endpoints, all related to coronary atherosclerosis. The majority of these disease endpoints are highly overlapping and representing major coronary heart disease (CHD) event. For this variant, we did not detect other phenome-wide significant associations among the 2 861 endpoints in our data. Risk-lowering effect of rs534125149 on CHD was replicated in Biobank Japan <sup>22, 23</sup> (BBJ) and the Estonian Biobank (EstBB) <sup>21</sup> (35 644 cases and 328 461 controls total: OR = 0.754 [0.67-0.84], p = 5.41×10<sup>-7</sup>). Association results for rs534125149 with CHD and MI across different cohorts are shown in **Supplementary Figure 4**.




**Figure 2**: Phenome-wide association study (PheWAS) results for rs534125149. Total number of tested endpoints is 2 861 (A complete list of endpoints analyzed and their definitions is available at <a href="https://www.finngen.fi/en/researchers/clinical-endpoints">https://www.finngen.fi/en/researchers/clinical-endpoints</a>). The dashed line represents the phenome-wide significance threshold, multiple testing corrected by the number of endpoints = 0.05/2 861 =  $1.75 \times 10^{-5}$ . All endpoints reaching that threshold are labelled in the figure.

## Splice acceptor variant rs201988637 in MFGE8

In addition to inframe insertion rs53412514, we also identified a splice acceptor variant (rs201988637) in *MFGE8* to have a protective effect on coronary atherosclerosis (OR = 0.72 [0.63-0.83], p =  $7.94 \times 10^{-06}$ ) and related endpoints. The splice acceptor variant had very similar PheWAS profile as the indel (**Supplementary Figure 5**) and furthermore the two variants had very similar protective effect sizes for the endpoints (**Figure 3** and **Supplementary Table 1**). Similar to rs534125149, this variant is also highly enriched in Finland (37- fold compared to NFE), allele

frequency in Finland being 0.6 %. Moreover, both the splice acceptor and the inframe insertion variants were enriched to Eastern Finland (**Supplementary Figure 6**).



**Figure 3:** Comparison of the effects (OR) of rs534125149 and rs201988637 for 14 endpoints with p-value  $< 1.75 \times 10$ -5 (PWS) for rs534125149. 95% confidence intervals represented as grey lines.

These two variants (rs534125149 and rs201988637) are in low linkage disequilibrium (LD, r<sup>2</sup> = 0.00015) and did not have any effect on the other variant's associations with coronary atherosclerosis or MI (**Table 3** and **Supplementary Figure 7**). This indicates that they both have their own, independent protective effect against these endpoints.

### **Table 3:** Results of the conditional analysis on MI and coronary atherosclerosis.


Phenotype	SNPID [chr:position:ref:alt]	Most severe	Original GWA	S results	Conditional	results
1 henotype	(rsid)	consequence	OR [CI]	P-value	OR [CI]	P-value
Coronary	chr15:88901702:C:CTGT (rs534125149)	Inframe insertion	0.75 [0.71-0.81]	2.63×10 <sup>-16</sup>	0.75 [0.70-0.80] a	7.68×10 <sup>-15</sup> a
atherosclerosis	chr15:88899813:T:G (rs201988637)	Splice acceptor variant	0.72 [0.63-0.83]	7.94×10 <sup>-6</sup>	0.73 [0.64-0.85] ь	1.99×10 <sup>-5</sup> b
Myocardial infarction,	chr15:88901702:C:CTGT (rs534125149)	Inframe insertion	0.74 [0.68-0.81]	1.95×10-11	0.79 [0.73-0.85] a	1.92×10 <sup>-10</sup> a
strict	chr15:88899813:T:G (rs201988637)	Splice acceptor variant	0.69 [0.58-0.83]	9.62×10 <sup>-5</sup>	0.71 [0.59-0.85] b	4.03×10 <sup>-4</sup> b

This table present the conditional analysis results for coronary atherosclerosis and MI (strict definition, only primary diagnoses accepted) where the association has been conditioned on rs534125149 and rs201988637 separately

- <sup>a</sup> Conditional on rs201988637
- <sup>b</sup> Conditional on rs534125149

# Survival analysis

In addition to protection against coronary atherosclerosis and myocardial infarction, both the infame insertion rs534125149 and splice acceptor variant rs201988637 showed also significant association in survival analysis when analyzing survival time from birth to first diagnose of coronary atherosclerosis (HR = 0.78 [0.74-0.93]),  $p = 1.67 \times 10^{-17}$  and HR = 0.77 [0.69-0.88],  $p = 5.08 \times 10^{-05}$ , respectively) and myocardial infarction (HR = 0.86 [0.80-0.93],  $p = 2.63 \times 10^{-10}$  and HR = 0.72 [0.61-0.85],  $p = 8.16 \times 10^{-05}$ ). In addition, when combining the heterozygous and homozygous carriers of both rs534125149 and rs201988637 together, carriers get the first diagnose significantly later than non-carriers (HR = 0.81 [0.77-0.85],  $p = 6.4 \times 10^{-16}$  for coronary atherosclerosis and HR = 0.78 [0.72-0.85],  $p = 1.16 \times 10^{-11}$  for MI) (**Figure 4**).



**Figure 4**: Cumulative incidence plots for myocardial infarction. Red line represents carriers (homoor heterozygous) for either rs534125149 or rs201988637, and blue line represent non-carriers. Dashed lines represent 95%- confidence intervals.

Associations with risk factors for CVD and coronary heart disease sub-types We then tested for possible associations between the *MFGE8* variants and risk factors for CVD. The splice acceptor variant rs201988637 was associated with pulse pressure in analyses across four cohorts with pulse pressure measurements and variant rs201988637 available, with the risk lowering allele associated with lower pulse pressure (p =  $1.08 \times 10^{-03}$ ,  $\beta$  = -1.52 [-2.43- -0.61]) mmHg (**Figure 5**). In addition, rs534125149 was significantly associated with height, but further analysis pointed this signal to be reflecting the association of a known association of *ACAN* with

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320


321

322

323

324

height, located near MFGE8 (Supplementary material, Supplementary Figure 8). No associations with other risk factors were observed. In the Corogene cohort (n = 4.896), rs534125149 significantly (p < 0.05) lowers the risk for acute coronary syndrome and stable coronary heart disease (RR = 0.87 and 0.83, respectively) compared to healthy controls, but not against other types of heart attack, further pointing to a specific risklowering effect of MFGE8 on ischemic heart diseases (Supplementary Figure 9). Previously reported common variants near MFGE8 Previously, common intergenic variant (rs8042271) near MFGE8 has been reported to associate with coronary heart disease (CHD) risk<sup>3, 27</sup>. We replicate this association (OR = 0.90, p =  $3.69 \times 10^{-10}$  for coronary atherosclerosis) in FinnGen. LD between the common variant rs8042271 and the inframe insertion rs534125149 is 0.154. The LD characteristics for all 3 variants in MFGE8 (rs534125149, rs201988637 and rs8042271) in FinnGen are in Supplementary Table 2. Common variant rs8042271 was in the 95% credible set for MI with the causal probability of 0.003 but was not included in the 95% credible sets for coronary atherosclerosis (Supplementary Table 3 and **Supplementary Table 4**). The conditional analyses of all three *MFGE8* variants showed that the association of the previously reported common variant rs8042271 can be explained by the inframe insertion variant rs534125149, but not vice versa, and that the association of the splice acceptor variant rs201988637 is independent of both rs534125149 and rs8042271 (Supplementary Table 5).



**Figure 5**: Results for pulse pressure association across all cohorts with splice acceptor variant rs201988637 present.

# Fine-mapping of the MFGE8 locus

In our fine-mapping analyses, MI had most probably one credible set (set of causal variants) of 32 variants with the highest posterior probability (posterior probability = 0.62), and coronary atherosclerosis had two credible sets of 6 and 45 variants, respectively, with the highest posterior probability (posterior probability = 0.74). For both MI and coronary atherosclerosis, rs534125149 had the highest probability of being causal (probability of being causal = 0.250 and 0.318, respectively) and was included in the first credible set (Supplementary Table 3, Supplementary Table 4 and Supplementary Figure 10). Splice acceptor variant rs201988637 was not included in the credible sets for either MI or coronary atherosclerosis, whereas previously reported common

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

variant rs8042271 was included in the credible set for MI with the probability of being causal = 0.003(Supplementary Table 3). Discussion Here we show that a loss of function for MFGE8 leads to 28% lower risk of myocardial infarction and reduces risk for other coronary atherosclerosis-related diseases. The effects are specific to coronary heart disease events and no significant association was observed to other diseases in a phenome-wide search, even if this can be due to lower statistical power in rare disease endpoints. Loss-of-function of MFGE8 was also associated with lower pulse pressure, but not with blood lipids, blood pressure or other known coronary heart disease risk factors. In addition to MFGE8, we report three other novel loci associated with coronary atherosclerosis risk, and to our knowledge we report the first CHD associated locus, *FHL1*, in chromosome X. Our findings allow us to draw several conclusions. First, MFGE8 is a potential intervention target with specific effects on coronary heart disease. Specific protective effect with the LoF in MFGE8 shows potential for efficacy of a treatment targeting MFGE8 protein or downstream products. Second, the lack of risk elevation in other diseases provide evidence on the potential safety of the intervention. Previously, the protective effect of loss-of-function variants have been reported for example for PCSK95 and APOC36, and in phase I, II and III trials, inhibition of PCSK9 have led to significantly decreased LDL-C levels, and in short-term trials, PCSK9 inhibitors have been welltolerated and have had a low incidence of adverse effects.<sup>28</sup> Based on the phenome-wide association profile for the loss-of-function variant, we hypothesize that inhibiting MFGE8 could lower the CHD risk.

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

An association of loss-of-function of MFGE8 with lower pulse pressure, a potential biomarker for arterial stiffness <sup>29</sup>, are very much in line with previous studies on MFGE8 and the inflammatory ageing process of the arteries, highlighting the possible role of MFGE8 in arterial ageing and stiffness. The MFGE8 gene encodes Milk-fat globule-EGF 8 (MFGE8), or lactadherin, which is an integrin-binding glycoprotein implicated in vascular smooth muscle cell (VSMC) proliferation and invasion, and the secretion of pro-inflammatory molecules 30,31. Lactadherin is known to play important roles in several other biological processes, including apoptotic cell clearance and adaptive immunity <sup>32</sup>, which are known to contribute to the pathogenesis of ischemic stroke. Initially lactadherin was identified as a bridging molecule between apoptotic cells and phagocytic macrophages 33-35, but a growing evidence has indicated that it is a secreted inflammatory mediator that orchestrates diverse cellular interactions involved in the pathogenesis of various diseases, including vascular metabolic disorders and some tumors <sup>36-40</sup> and cancers, such as breast <sup>38,41</sup>, bladder<sup>42</sup>, esophageal<sup>43</sup> and colorectal cancer <sup>44</sup>. Recently, not only has MFG-E8 expression emerged as a molecular hallmark of adverse cardiovascular remodeling with age 45-48, but MFG-E8 signaling has also been found to mediate the vascular outcomes of cellular and matrix responses to the hostile stresses associated with hypertension, diabetes, and atherosclerosis <sup>49-53</sup>. Arterial inflammation and remodeling are linked to the pathogenesis of age-associated arterial diseases, such as atherosclerosis. Recently, lactadherin has been identified as a novel local biomarker for ageing arterial walls by high-throughput proteomic screening, and it has been shown to also be an element of the arterial inflammatory signaling network 54. The transcription, translation, and signaling levels of MFG-E8 are increased in aged, atherosclerotic, hypertensive, and diabetic arterial walls in vivo, as well as activated VSMCs and a subset of macrophages in vitro. During aging, both MFG-E8 transcription and translation increase within the arterial walls and hearts of various species, including rats, humans, and monkeys<sup>48,55-57</sup>, and MFG-E8 is markedly

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

up-regulated in rat aortic walls with ageing<sup>48</sup>. High levels of MFG-E8 have also been detected within endothelial cells, SMC, and macrophages of atherosclerotic aortae in both mice and humans<sup>53,58</sup>. Furthermore, in the advanced atherosclerotic plaques found in murine models, decreased macrophage MFG-E8 levels are associated with an inhibition of apoptotic cell engulfment, leading to the accumulation of cellular debris during the pathogenesis of atherosclerosis. Lastly, lactadherin has shown tissue protection in various models of organ injury, including suppression of inflammation and apoptosis in intestinal ischemia in mice <sup>59</sup>, as well as inducing recovery from ischemia by facilitating angiogenesis 60. Our study does, however, have a few limitations. First, our primary association results come from Finnish population with considerable elevation in allele frequency in MFGE8 variants among Finns. Therefore, the replication of the association in other populations has reduced statistical power. However, there were enough carriers combined in Japanese, Estonian and UK samples to replicate robustly both the protective association with coronary artery disease and for pulse pressure. Secondly, although our data shows association with pulse pressure which has previously been linked to arterial stiffness, the direct effect of the genetic variants on arterial stiffness and arterial aging needs further evidence. In conclusion, our results show that inhibiting production of lactadherin could reduce the risk for coronary atherosclerosis substantially and thus present MFGE8 as a potential therapeutical target for atherosclerotic cardiovascular disease. Our study also highlights the potential of FinnGen, as a largescale biobank study in isolated population to identify high-impact variants either very rare or absent in other populations.

- 1. Kessler, T., Erdmann, J. & Schunkert, H. Genetics of coronary artery disease and myocardial
- 414 infarction-2013. Curr. Cardiol. Rep. **15**, 368 (2013).
- 415 2. O'Donnell, C. J. & Nabel, E. G. Genomics of cardiovascular disease. N. Engl. J. Med. 365, 2098-
- 416 2109 (2011).
- 3. Nikpay, M. et al. A comprehensive 1000 Genomes-based genome-wide association meta-
- analysis of coronary artery disease. *Nat. Genet.* **47**, 1121 (2015).
- 4. Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the Finnish
- founder population. *PLoS genetics* **10** (2014).
- 5. Cohen, J. C., Boerwinkle, E., Mosley Jr, T. H. & Hobbs, H. H. Sequence variations in PCSK9,
- low LDL, and protection against coronary heart disease. N. Engl. J. Med. **354**, 1264-1272 (2006).
- 423 6. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and
- Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. *N. Engl.*
- 425 *J. Med.* **371**, 22-31 (2014).
- 7. Dewey, F. E. *et al.* Inactivating variants in ANGPTL4 and risk of coronary artery disease. *N*.
- 427 Engl. J. Med. 374, 1123-1133 (2016).
- 428 8. Libby, P. et al. Lewis EF. Atherosclerosis. Nature reviews Disease primers 5, 56 (2019).
- 9. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456
- 430 humans. *Nature* **581**, 434-443 (2020).
- 431 10. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in
- large-scale genetic association studies. *Nat. Genet.* **50**, 1335-1341 (2018).
- 433 11. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 47, D1005-D1012 (2018).
- 435 12. Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-wide
- 436 association studies. *Bioinformatics* **32**, 1493-1501 (2016).
- 437 13. Vaara, S. *et al.* Cohort profile: the Corogene study. *Int. J. Epidemiol.* **41**, 1265-1271 (2012).
- 438 14. Dey, R. et al. An efficient and accurate frailty model approach for genome-wide survival
- association analysis controlling for population structure and relatedness in large-scale biobanks.
- 440 bioRxiv (2020).
- 15. Breslow, N. E. & Clayton, D. G. Approximate inference in generalized linear mixed models.
- 442 *Journal of the American statistical Association* **88**, 9-25 (1993).
- 16. Chen, H. et al. Control for population structure and relatedness for binary traits in genetic
- association studies via logistic mixed models. The American Journal of Human Genetics 98, 653-
- 445 666 (2016).

- 446 17. Borodulin, K. et al. Forty-year trends in cardiovascular risk factors in Finland. The European
- 447 *Journal of Public Health* **25**, 539-546 (2014).
- 18. Widen, E. et al. Communicating polygenic and non-genetic risk for atherosclerotic
- cardiovascular disease-An observational follow-up study. *medRxiv* (2020).
- 450 19. Raitakari, O. T. et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int. J.
- 451 Epidemiol. 37, 1220-1226 (2008).
- 452 20. Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using
- population-specific high-coverage WGS-based imputation reference panel. European Journal of
- 454 *Human Genetics* **25**, 869 (2017).
- 455 21. Leitsalu, L. et al. Cohort profile: Estonian biobank of the Estonian genome center, university of
- 456 Tartu. Int. J. Epidemiol. 44, 1137-1147 (2015).
- 457 22. Nagai, A. et al. Overview of the BioBank Japan Project: study design and profile. Journal of
- 458 *epidemiology* **27**, S2-S8 (2017).
- 459 23. Sakaue, S. et al. A global atlas of genetic associations of 220 deep phenotypes. medRxiv,
- 460 2020.10. 23.20213652 (2021).
- 24. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*
- **462 562**, 203 (2018).
- 463 25. Cooper, H., Hedges, L. V. & Valentine, J. C. in The handbook of research synthesis and meta-
- analysis (Russell Sage Foundation, 2019).
- 465 26. Evangelou, E. & Ioannidis, J. P. Meta-analysis methods for genome-wide association studies
- 466 and beyond. *Nature Reviews Genetics* **14**, 379-389 (2013).
- 27. Soubeyrand, S. et al. Regulation of MFGE8 by the intergenic coronary artery disease locus on
- 468 15q26. 1. *Atherosclerosis* **284**, 11-17 (2019).
- 28. Dadu, R. T. & Ballantyne, C. M. Lipid lowering with PCSK9 inhibitors. *Nature Reviews*
- 470 *Cardiology* **11**, 563 (2014).
- 471 29. Benetos, A. et al. Mortality and cardiovascular events are best predicted by low
- central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly
- 473 nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness
- 474 in Institutionalized Very Aged Population) study. J. Am. Coll. Cardiol. **60**, 1503-1511 (2012).
- 30. Oshima, K. et al. Lactation-Dependent Expression of an mRNA Splice Variant with an Exon for
- a MultiplyO-Glycosylated Domain of Mouse Milk Fat Globule Glycoprotein MFG-E8. *Biochem*.
- 477 *Biophys. Res. Commun.* **254**, 522-528 (1999).
- 478 31. Aoki, N. et al. Immunologically cross-reactive 57 kDa and 53 kDa glycoprotein antigens of
- bovine milk fat globule membrane: isoforms with different N-linked sugar chains and differential
- 480 glycosylation at early stages of lactation. Biochimica et Biophysica Acta (BBA)-General Subjects
- 481 **1200**, 227-234 (1994).

- 482 32. Deroide, N. et al. MFGE8 inhibits inflammasome-induced IL-1β production and limits
- 483 postischemic cerebral injury. *J. Clin. Invest.* **123**, 1176-1181 (2013).
- 484 33. Hanayama, R. et al. Identification of a factor that links apoptotic cells to phagocytes. *Nature*
- **485 417**, 182-187 (2002).
- 486 34. Hanayama, R. et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-
- 487 deficient mice. *Science* **304**, 1147-1150 (2004).
- 488 35. Yoshida, H. et al. Phosphatidylserine-dependent engulfment by macrophages of nuclei from
- 489 erythroid precursor cells. *Nature* **437**, 754-758 (2005).
- 36. Tahara, H. et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on
- 491 Immunological Molecular Markers in Oncology. *Journal of Translational Medicine* **7**, 1-25 (2009).
- 492 37. Neutzner, M. et al. MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent
- transgenic mouse model of multistage carcinogenesis. *Cancer Res.* **67**, 6777-6785 (2007).
- 494 38. TAYLOR, M. R., COUTO, J. R., SCALLAN, C. D., CERIANI, R. L. & PETERSON, J. A.
- 495 Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and
- breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 16, 861-
- 497 869 (1997).
- 498 39. Jinushi, M. et al. Milk fat globule EGF-8 promotes melanoma progression through coordinated
- 499 Akt and twist signaling in the tumor microenvironment. Cancer Res. 68, 8889-8898 (2008).
- 40. Raymond, A., Ensslin, M. A. & Shur, B. D. SED1/MFG-E8: a bi-motif protein that orchestrates
- diverse cellular interactions. J. Cell. Biochem. 106, 957-966 (2009).
- 502 41. Yu, L. et al. MFG-E8 overexpression is associated with poor prognosis in breast cancer
- patients. *Pathology-Research and Practice* **215**, 490-498 (2019).
- 504 42. Sugano, G. et al. Milk fat globule—epidermal growth factor—factor VIII (MFGE8)/lactadherin
- promotes bladder tumor development. *Oncogene* **30**, 642-653 (2011).
- 506 43. Kanemura, T. et al. Immunoregulatory influence of abundant MFG-E8 expression by
- esophageal cancer treated with chemotherapy. *Cancer science* **109**, 3393-3402 (2018).
- 508 44. Jia, M. et al. Prognostic correlation between MFG-E8 expression level and colorectal Cancer.
- 509 Arch. Med. Res. 48, 270-275 (2017).
- 510 45. Wang, M., Khazan, B. & G Lakatta, E. Central arterial aging and angiotensin II signaling.
- 511 *Current hypertension reviews* **6**, 266-281 (2010).
- 512 46. Wang, M., Monticone, R. E. & Lakatta, E. G. Arterial aging: a journey into subclinical arterial
- 513 disease. Curr. Opin. Nephrol. Hypertens. 19, 201 (2010).
- 514 47. Ortiz, A. et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.
- 515 *Nature reviews Nephrology* **8**, 141 (2012).

- 48. Fu, Z. et al. Milk fat globule protein epidermal growth factor-8: a pivotal relay element within
- 517 the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular
- smooth muscle cells invasion. *Circ. Res.* **104**, 1337-1346 (2009).
- 49. Bagnato, C. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility
- study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry.
- 521 *Molecular & Cellular Proteomics* **6**, 1088-1102 (2007).
- 522 50. Li, X. et al. Proteomics approach to study the mechanism of action of grape seed
- 523 proanthocyanidin extracts on arterial remodeling in diabetic rats. *Int. J. Mol. Med.* **25**, 237-248
- 524 (2010).
- 525 51. Strøm, C. C. et al. Identification of a core set of genes that signifies pathways underlying
- 526 cardiac hypertrophy. Comp. Funct. Genomics 5, 459-470 (2004).
- 527 52. Lin, Y. et al. Comparative proteomic analysis of rat aorta in a subtotal nephrectomy model.
- 528 *Proteomics* **10**, 2429-2443 (2010).
- 529 53. Ait-Oufella, H. et al. CLINICAL PERSPECTIVE. Circulation 115, 2168-2177 (2007).
- 530 54. Wang, M., H Wang, H. & G Lakatta, E. Milk fat globule epidermal growth factor VIII signaling
- in arterial wall remodeling. Current vascular pharmacology 11, 768-776 (2013).
- 532 55. Peng, S., Glennert, J. & Westermark, P. Medin-amyloid: a recently characterized age-associated
- arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 12, 96-102
- 534 (2005).
- 535 56. Peng, S. et al. Medin and medin-amyloid in ageing inflamed and non-inflamed temporal
- arteries. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and
- 537 *Ireland* **196**, 91-96 (2002).
- 538 57. Grant, J. E. et al. Quantification of protein expression changes in the aging left ventricle of
- Rattus norvegicus. *Journal of proteome research* **8**, 4252-4263 (2009).
- 540 58. Bagnato, C. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility
- study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry.
- 542 *Molecular & Cellular Proteomics* **6**, 1088-1102 (2007).
- 543 59. Cheyuo, C. et al. Recombinant human MFG-E8 attenuates cerebral ischemic injury: its role in
- anti-inflammation and anti-apoptosis. *Neuropharmacology* **62**, 890-900 (2012).
- 60. Silvestre, J. et al. Lactadherin promotes VEGF-dependent neovascularization. Nat. Med. 11,
- 546 499-506 (2005).

549

# 548 Acknowledgements

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

We would like to thank all participants of all study cohorts for their generous participation. We also want to thank Dr. Kaoru Ito at RIKEN Center for Integrative Medical Sciences for supporting the study. This work was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062 and 336820 to S.R.), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation, University of Helsinki HiLIFE Fellow, Grand Challenge grants and Horizon 2020 Research and Innovation Programme (grant number 101016775 "INTERVENE" to S.R.), Academy of Finland grant number 331671 to N.M., the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.16-0125 to L.M.), the Estonian Research Council grant PRG184 [to L.M.] and the Doctoral Programme in Population Health, University of Helsinki [to S.E.R.]. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Celgene Corporation, Celgene International II Sarl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are acknowledged for deliverig biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) Terveystalo and Biobank 574 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are 575 members of BBMRI.fi infrastructure (www.bbmri.fi) and FinBB (https://finbb.fi/). 576 Estonian Biobank research team 577 578 Tõnu Esko, 579 Andres Metspalu, 580 Reedik Mägi, Mari Nelis 582 583 Contributors of FinnGen 584 **Steering Committee** 585 Aarno Palotie Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 586 Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 587 588 Pharmaceutical companies 589 **Bridget Riley-Gills** Abbvie, Chicago, IL, United States 590 Howard Jacob Abbvie, Chicago, IL, United States Dirk Paul Astra Zeneca, Cambridge, United Kingdom 592 Heiko Runz Biogen, Cambridge, MA, United States 593 Sally John Biogen, Cambridge, MA, United States 594 Robert Plenge Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States 595 Mark McCarthy Genentech, San Francisco, CA, United States 596 Julie Hunkapiller Genentech, San Francisco, CA, United States 597 Meg Ehm GlaxoSmithKline, Brentford, United Kingdom 598 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom 599 Caroline Fox Merck, Kenilworth, NJ, United States 600 Anders Mälarstig Pfizer, New York, NY, United States Katherine Klinger Sanofi, Paris, France 602 Deepak Raipal Sanofi, Paris, France

581

591

601

603	Tim Behrens	Maze Therapeutics, San Francisco, CA, United States
604	Robert Yang	Janssen Biotech, Beerse, Belgium
605	Richard Siegel	Novartis, Basel, Switzerland
606	University of Helsinki &	z Biobanks
607	Tomi Mäkelä	HiLIFE, University of Helsinki, Finland, Finland
608	Jaakko Kaprio	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland
609	Petri Virolainen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
610	Finland	
611	Antti Hakanen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku,
612	Finland	
613	Terhi Kilpi	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
614	Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
615	Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
616	Helsinki, Finland	
617	Anne Pitkäranta	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
618	Helsinki	
619	Juhani Junttila	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
620	District, Oulu, Finland	
621	Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
622	District, Oulu, Finland	
623	Tarja Laitinen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
624	Tampere, Finland	
625	Johanna Mäkelä	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
626	Tampere, Finland	
627	Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
628	Kuopio, Finland	
629	Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
630	Jyväskylä, Finland	
631		

### **Other Experts/ Non-Voting Members**

632

633	Outi Tuovila	Business Finland, Helsinki, Finland
634	Raimo Pakkanen	Business Finland, Helsinki, Finland
635		
636	Scientific Committee	
637	Pharmaceutical compani	ies
638	Jeffrey Waring	Abbvie, Chicago, IL, United States
639	Ali Abbasi	Abbvie, Chicago, IL, United States
640	Mengzhen Liu	Abbvie, Chicago, IL, United States
641	Ioanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom
642	Chia-Yen Chen	Biogen, Cambridge, MA, United States
643	Heiko Runz	Biogen, Cambridge, MA, United States
644	Shameek Biswas	Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States
645	Julie Hunkapiller	Genentech, San Francisco, CA, United States
646	Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom
647	Neha Raghavan	Merck, Kenilworth, NJ, United States
648	Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States
649	Anders Mälarstig	Pfizer, New York, NY, United States
650	Xinli Hu	Pfizer, New York, NY, United States
651	Katherine Klinger	Sanofi, Paris, France
652	Matthias Gossel	Sanofi, Paris, France
653	Robert Graham	Maze Therapeutics, San Francisco, CA, United States
654	Tim Behrens	Maze Therapeutics, San Francisco, CA, United States
655	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
656	Wilco Fleuren	Janssen Biotech, Beerse, Belgium
657	Dawn Waterworth	Janssen Biotech, Beerse, Belgium
658	Nicole Renaud	Novartis, Basel, Switzerland
659	Ma'en Obeidat	Novartis, Basel, Switzerland
660		
661	University of Helsinki &	Biobanks
662	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland

663	Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
664	Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
665	Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
666	Helsinki, Finland	
667	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
668	Helsinki	
669	Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
670	District, Oulu, Finland	
671	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
672	District, Oulu, Finland	
673	Johanna Mäkelä	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
674	Tampere, Finland	
675	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital
676	District, Kuopio, Finland	
677	Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
678	Jyväskylä, Finland	
679	Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
680	Jyväskylä, Finland	
681		
682	Clinical Groups	
683	Neurology Group	
684	Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland
685	Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland
686	Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland
687	Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland
688	Mikko Hiltunen	Northern Savo Hospital District, Kuopio, Finland
689	Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland
690	Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
691	Juha Rinne	Hospital District of Southwest Finland, Turku, Finland
692	Roosa Kallionpää	Hospital District of Southwest Finland, Turku, Finland

693	Ali Abbasi	Abbvie, Chicago, IL, United States
694	Adam Ziemann	Abbvie, Chicago, IL, United States
695	Jeffrey Waring	Abbvie, Chicago, IL, United States
696	Sahar Esmaeeli	Abbvie, Chicago, IL, United States
697	Nizar Smaoui	Abbvie, Chicago, IL, United States
698	Anne Lehtonen	Abbvie, Chicago, IL, United States
699	Susan Eaton	Biogen, Cambridge, MA, United States
700	Heiko Runz	Biogen, Cambridge, MA, United States
701	Sanni Lahdenperä	Biogen, Cambridge, MA, United States
702	Janet van Adelsberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
703	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
704	Julie Hunkapiller	Genentech, San Francisco, CA, United States
705	Natalie Bowers	Genentech, San Francisco, CA, United States
706	Edmond Teng	Genentech, San Francisco, CA, United States
707	Sarah Pendergrass	Genentech, San Francisco, CA, United States
708	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
709	Kari Linden	Pfizer, New York, NY, United States
710	Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom
711	David Pulford	GlaxoSmithKline, Brentford, United Kingdom
712	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
713	Laura Addis	GlaxoSmithKline, Brentford, United Kingdom
714	John Eicher	GlaxoSmithKline, Brentford, United Kingdom
715	Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
716	Sarah Pendergrass	Genentech, San Francisco, CA, United States
717	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
718	Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
719		
720	Gastroenterology Group	
721	Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
722	Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland

723	Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
724	Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland
725	Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland
726	Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland
727	Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland
728	Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland
729	Ali Abbasi	Abbvie, Chicago, IL, United States
730	Graham Heap	Abbvie, Chicago, IL, United States
731	Jeffrey Waring	Abbvie, Chicago, IL, United States
732	Nizar Smaoui	Abbvie, Chicago, IL, United States
733	Fedik Rahimov	Abbvie, Chicago, IL, United States
734	Anne Lehtonen	Abbvie, Chicago, IL, United States
735	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
736	Tim Lu	Genentech, San Francisco, CA, United States
737	Natalie Bowers	Genentech, San Francisco, CA, United States
738	Danny Oh	Genentech, San Francisco, CA, United States
739	Sarah Pendergrass	Genentech, San Francisco, CA, United States
740	Kirsi Kalpala	Pfizer, New York, NY, United States
741	Melissa Miller	Pfizer, New York, NY, United States
742	Xinli Hu	Pfizer, New York, NY, United States
743	Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom
744	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
745	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
746		
747	Rheumatology Group	
748	Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
749	Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland
750	Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland
751	Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland
752	Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland

753	Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland
754	Ali Abbasi	Abbvie, Chicago, IL, United States
755	Jeffrey Waring	Abbvie, Chicago, IL, United States
756	Fedik Rahimov	Abbvie, Chicago, IL, United States
757	Apinya Lertratanakul	Abbvie, Chicago, IL, United States
758	Nizar Smaoui	Abbvie, Chicago, IL, United States
759	Anne Lehtonen	Abbvie, Chicago, IL, United States
760	David Close	Astra Zeneca, Cambridge, United Kingdom
761	Marla Hochfeld	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
762	Natalie Bowers	Genentech, San Francisco, CA, United States
763	Sarah Pendergrass	Genentech, San Francisco, CA, United States
764	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
765	Kirsi Kalpala	Pfizer, New York, NY, United States
766	Nan Bing	Pfizer, New York, NY, United States
767	Xinli Hu	Pfizer, New York, NY, United States
768	Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom
769	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
770	Dawn Waterworth	Janssen Biotech, Beerse, Belgium
771	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland
772		
773	Pulmonology Group	
774	Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland
775	Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland
776	Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
777	Hannu Kankaanranta	Pirkanmaa Hospital District, Tampere, Finland
778	Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland
779	Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland
780	Nizar Smaoui	Abbvie, Chicago, IL, United States
781	Alex Mackay	Astra Zeneca, Cambridge, United Kingdom
782	Glenda Lassi	Astra Zeneca, Cambridge, United Kingdom

783	Susan Eaton	Biogen, Cambridge, MA, United States
784	Steven Greenberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
785	Hubert Chen	Genentech, San Francisco, CA, United States
786	Sarah Pendergrass	Genentech, San Francisco, CA, United States
787	Natalie Bowers	Genentech, San Francisco, CA, United States
788	Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom
789	Soumitra Ghosh	GlaxoSmithKline, Brentford, United Kingdom
790	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
791	Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom
792	Sina Rüeger	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
793		
794	Cardiometabolic Diseas	ses Group
795	Teemu Niiranen	The National Institute of Health and Welfare Helsinki, Finland
796	Felix Vaura	The National Institute of Health and Welfare Helsinki, Finland
797	Veikko Salomaa	The National Institute of Health and Welfare Helsinki, Finland
798	Markus Juonala	Hospital District of Southwest Finland, Turku, Finland
799	Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland
800	Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland
801	Juhani Junttila	Northern Ostrobothnia Hospital District, Oulu, Finland
802	Markku Laakso	Northern Savo Hospital District, Kuopio, Finland
803	Jussi Pihlajamäki	Northern Savo Hospital District, Kuopio, Finland
804	Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
805	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
806	Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
807	Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
808	Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland
809	Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom
810	Dirk Paul	Astra Zeneca, Cambridge, United Kingdom
811	Julie Hunkapiller	Genentech, San Francisco, CA, United States
812	Natalie Bowers	Genentech, San Francisco, CA, United States

813	Sarah Pendergrass	Genentech, San Francisco, CA, United States
814	Onuralp Soylemez	Merck, Kenilworth, NJ, United States
815	Jaakko Parkkinen	Pfizer, New York, NY, United States
816	Melissa Miller	Pfizer, New York, NY, United States
817	Russell Miller	Pfizer, New York, NY, United States
818	Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom
819	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
820	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
821	Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
822	Institute, Cambridge, MA	, United States
823	Joel Rämö	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
824	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
825	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
826	Sanni Ruotsalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
827		
828	Oncology Group	
828 829	Oncology Group Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
	<u>.</u>	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland
829	Tuomo Meretoja	•
829 830	Tuomo Meretoja Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
829 830 831	Tuomo Meretoja Heikki Joensuu Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland
829 830 831 832	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland
829 830 831 832 833	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
829 830 831 832 833 834	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland
829 830 831 832 833 834 835	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen Peeter Karihtala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland
829 830 831 832 833 834 835 836	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen Peeter Karihtala Saila Kauppila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland
829 830 831 832 833 834 835 836 837	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen Peeter Karihtala Saila Kauppila Päivi Auvinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland
829 830 831 832 833 834 835 836 837	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen Peeter Karihtala Saila Kauppila Päivi Auvinen Klaus Elenius	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku, Finland
829 830 831 832 833 834 835 836 837 838	Tuomo Meretoja Heikki Joensuu Olli Carpén Lauri Aaltonen Johanna Mattson Annika Auranen Peeter Karihtala Saila Kauppila Päivi Auvinen Klaus Elenius Johanna Schleutker	Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku, Finland Hospital District of Southwest Finland, Turku, Finland

843	Anne Lehtonen	Abbvie, Chicago, IL, United States
844	Jennifer Schutzman	Genentech, San Francisco, CA, United States
845	Julie Hunkapiller	Genentech, San Francisco, CA, United States
846	Natalie Bowers	Genentech, San Francisco, CA, United States
847	Sarah Pendergrass	Genentech, San Francisco, CA, United States
848	Andrey Loboda	Merck, Kenilworth, NJ, United States
849	Aparna Chhibber	Merck, Kenilworth, NJ, United States
850	Heli Lehtonen	Pfizer, New York, NY, United States
851	Stefan McDonough	Pfizer, New York, NY, United States
852	Marika Crohns	Sanofi, Paris, France
853	Sauli Vuoti	Sanofi, Paris, France
854	Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom
855	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
856	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
857	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
858	Mark Daly	$In stitute\ for\ Molecular\ Medicine\ Finland, HiLIFE, University\ of\ Helsinki, Finland$
858 859	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
	Mark Daly  Opthalmology Group	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
859	·	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland  Northern Savo Hospital District, Kuopio, Finland
859 860	Opthalmology Group	
859 860 861	Opthalmology Group  Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland
859 860 861 862	Opthalmology Group  Kai Kaarniranta  Joni A Turunen	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland
859 860 861 862 863	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila	Northern Savo Hospital District, Kuopio, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland
859 860 861 862 863 864	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland
859 860 861 862 863 864 865	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen  Hannu Uusitalo  Vesa Aaltonen	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland
859 860 861 862 863 864 865 866	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen  Hannu Uusitalo  Vesa Aaltonen	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland
859 860 861 862 863 864 865 866 867	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen  Hannu Uusitalo  Vesa Aaltonen  Hannele Uusitalo-Järvine	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland In Pirkanmaa Hospital District, Tampere, Finland
859 860 861 862 863 864 865 866 867 868	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen  Hannu Uusitalo  Vesa Aaltonen  Hannele Uusitalo-Järvine  Marja Luodonpää	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland In Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland
859 860 861 862 863 864 865 866 867 868 869	Opthalmology Group  Kai Kaarniranta  Joni A Turunen  Terhi Ollila  Sanna Seitsonen  Hannu Uusitalo  Vesa Aaltonen  Hannele Uusitalo-Järvine  Marja Luodonpää  Nina Hautala	Northern Savo Hospital District, Kuopio, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Hospital District of Southwest Finland, Turku, Finland n Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Northern Ostrobothnia Hospital District, Oulu, Finland

873	Erich Strauss	Genentech, San Francisco, CA, United States			
874	Natalie Bowers	Genentech, San Francisco, CA, United States			
875	Hao Chen	Genentech, San Francisco, CA, United States			
876	Sarah Pendergrass	Genentech, San Francisco, CA, United States			
877	Anna Podgornaia	Merck, Kenilworth, NJ, United States			
878	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
879	Institute, Cambridge, MA	, United States			
880	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
881					
882	Dermatology Group				
883	Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland			
884	Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland			
885	Katariina Hannula-Jouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland			
886	Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland			
887	Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland			
888	Leena Koulu	Hospital District of Southwest Finland, Turku, Finland			
889	Kirsi Kalpala	Pfizer, New York, NY, United States			
890	Ying Wu	Pfizer, New York, NY, United States			
891	David Choy	Genentech, San Francisco, CA, United States			
892	Sarah Pendergrass	Genentech, San Francisco, CA, United States			
893	Nizar Smaoui	Abbvie, Chicago, IL, United States			
894	Fedik Rahimov	Abbvie, Chicago, IL, United States			
895	Anne Lehtonen	Abbvie, Chicago, IL, United States			
896	Dawn Waterworth	Janssen Biotech, Beerse, Belgium			
897					
898	<b>Odontology Group</b>				
899	Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland			
900	Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland			
901	Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland			
902	David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland			

903	Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
904	Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
905	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
906	Maria Siponen	Northern Savo Hospital District, Kuopio, Finland
907	Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland
908	Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland
909	Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland
910	Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland
911	Kirsi Sipilä	Northern Ostrobothnia Hospital District, Oulu, Finland
912	Sarah Pendergrass	Genentech, San Francisco, CA, United States
913		
914	Women's Health and Re	production Group
915	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
916	Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland
917	Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
918	Ilkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
919	Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland
920	Kari Nieminen	Pirkanmaa Hospital District, Tampere, Finland
921	Päivi Polo	Hospital District of Southwest Finland, Turku, Finland
922	Kaarin Mäkikallio	Hospital District of Southwest Finland, Turku, Finland
923	Eeva Ekholm	Hospital District of Southwest Finland, Turku, Finland
924	Marja Vääräsmäki	Northern Ostrobothnia Hospital District, Oulu, Finland
925	Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland
926	Laure Morin-Papunen	Northern Ostrobothnia Hospital District, Oulu, Finland
927	Marjo Tuppurainen	Northern Savo Hospital District, Kuopio, Finland
928	Katja Kivinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
929	Elisabeth Widen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
930	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
931	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
932	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

933	Liu Aoxing	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland		
934	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland		
935	Niko Välimäki	University of Helsinki, Helsinki, Finland		
936	Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland		
937	Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland		
938	Mikko Arvas	Finnish Red Cross Blood Service, Helsinki, Finland		
939	Jeffrey Waring	Abbvie, Chicago, IL, United States		
940	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States		
941	Mengzhen Liu	Abbvie, Chicago, IL, United States		
942	Janet Kumar	GlaxoSmithKline, Brentford, United Kingdom		
943	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom		
944	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland		
945	Sarah Pendergrass	Genentech, San Francisco, CA, United States		
946 947	FinnGen Analysis working group			
948	Justin Wade Davis	Abbvie, Chicago, IL, United States		
949	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States		
950	Danjuma Quarless	Abbvie, Chicago, IL, United States		
951	Fedik Rahimov	Abbvie, Chicago, IL, United States		
952	Sahar Esmaeeli	Abbvie, Chicago, IL, United States		
953	Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom		
954	Eleonor Wigmore	Astra Zeneca, Cambridge, United Kingdom		
955	Adele Mitchell	Biogen, Cambridge, MA, United States		
956	Benjamin Sun	Biogen, Cambridge, MA, United States		
957	Ellen Tsai	Biogen, Cambridge, MA, United States		
958	Denis Baird	Biogen, Cambridge, MA, United States		
959	Paola Bronson	Biogen, Cambridge, MA, United States		
960	Ruoyu Tian	Biogen, Cambridge, MA, United States		
961	Stephanie Loomis	Biogen, Cambridge, MA, United States		
962	Yunfeng Huang	Biogen, Cambridge, MA, United States		
963	Joseph Maranville	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		

964	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		
965	Elmutaz Mohammed	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		
966	Samir Wadhawan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		
967	Erika Kvikstad	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		
968	Minal Caliskan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States  Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States		
969	Diana Chang	Genentech, San Francisco, CA, United States		
970	Julie Hunkapiller	Genentech, San Francisco, CA, United States		
971	Tushar Bhangale	Genentech, San Francisco, CA, United States		
972	Natalie Bowers	Genentech, San Francisco, CA, United States		
973	Sarah Pendergrass	Genentech, San Francisco, CA, United States		
974	Kirill Shkura	Merck, Kenilworth, NJ, United States		
975	Victor Neduva	Merck, Kenilworth, NJ, United States		
976	Xing Chen	Pfizer, New York, NY, United States		
977	Åsa Hedman	Pfizer, New York, NY, United States		
978	Karen S King	GlaxoSmithKline, Brentford, United Kingdom		
979	Padhraig Gormley	GlaxoSmithKline, Brentford, United Kingdom		
980	Jimmy Liu	GlaxoSmithKline, Brentford, United Kingdom		
981	Clarence Wang	Sanofi, Paris, France		
982	Ethan Xu	Sanofi, Paris, France		
983	Franck Auge	Sanofi, Paris, France		
984	Clement Chatelain	Sanofi, Paris, France		
985	Deepak Rajpal	Sanofi, Paris, France		
986	Dongyu Liu	Sanofi, Paris, France		
987	Katherine Call	Sanofi, Paris, France		
988	Tai-He Xia	Sanofi, Paris, France		
989	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States		
990	Matt Brauer	Maze Therapeutics, San Francisco, CA, United States		
991	Huilei Xu	Novartis, Basel, Switzerland		
992	Amy Cole	Novartis, Basel, Switzerland		
993	Jonathan Chung	Novartis, Basel, Switzerland		

994	Jaison Jacob	Novartis, Basel, Switzerland			
995	Katrina de Lange	Novartis, Basel, Switzerland			
996	Jonas Zierer	Novartis, Basel, Switzerland			
997	Mitja Kurki	Novartis, Basel, Switzerland  Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
998	Institute, Cambridge, MA	A, United States			
999	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1000	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1001	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
1002	Institute, Cambridge, MA	A, United States			
1003	Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1004	Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1005	Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1006	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1007	Pietro Della Briotta Paro	lo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1008	Wei Zhou	Broad Institute, Cambridge, MA, United States			
1009	Mutaamba Maasha	Broad Institute, Cambridge, MA, United States			
1010	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1011	Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1012	Manuel Rivas	University of Stanford, Stanford, CA, United States			
1013	Aarno Palotie	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1014	Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1015	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1016	Vincent Llorens	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1017	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1018	Mari E Niemi	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1019	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1020	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1021	Henrike Heyne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1022	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1023	Kimmo Palin	University of Helsinki, Helsinki, Finland			

1024	Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland			
1025	Harri Siirtola	University of Tampere, Tampere, Finland			
1026	Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland			
1027	Jiwoo Lee	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
1028	Institute, Cambridge, MA	A, United States			
1029	Kristin Tsuo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
1030	Institute, Cambridge, MA, United States				
1031	Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad			
1032	Institute, Cambridge, MA	A, United States			
1033	Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland			
1034	Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,			
1035	Helsinki, Finland				
1036	Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland			
1037	Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland			
1038	Miika Koskinen	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,			
1039	Helsinki				
1040	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,			
1041	Helsinki				
1042	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital			
1043	District, Oulu, Finland				
1044	Katri Pylkäs	University of Oulu, Oulu, Finland			
1045	Marita Kalaoja	University of Oulu, Oulu, Finland			
1046	Minna Karjalainen	University of Oulu, Oulu, Finland			
1047	Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital			
1048	District, Oulu, Finland				
1049	Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,			
1050	Tampere, Finland				
1051	Sami Heikkinen	University of Eastern Finland, Kuopio, Finland			
1052	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,			
1053	Kuopio, Finland				

1054	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland		
1055	Samuel Heron	University of Tur	ku, Turku, Finland	
1056	Dhanaprakash Jambulinga	ım	University of Turku, Turku, Finland	
1057	Venkat Subramaniam Rat	hinakannan	University of Turku, Turku, Finland	
1058	Nina Pitkänen	Auria Biobank /	University of Turku / Hospital District of Southwest Finland, Turku,	
1059	Finland			
1060				
1061	Biobank directors			
1062	Lila Kallio	Auria Biobank /	University of Turku / Hospital District of Southwest Finland, Turku,	
1063	Finland			
1064	Sirpa Soini	THL Biobank / T	he National Institute of Health and Welfare Helsinki, Finland	
1065	Jukka Partanen	Finnish Red Cros	ss Blood Service / Finnish Hematology Registry and Clinical Biobank,	
1066	Helsinki, Finland			
1067	Eero Punkka	Helsinki Biobank	x / Helsinki University and Hospital District of Helsinki and Uusimaa,	
1068	Helsinki			
1069	Raisa Serpi	Northern Finland	Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital	
1070	District, Oulu, Finland			
1071	Johanna Mäkelä	Finnish Clinical	Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	
1072	Tampere, Finland			
1073	Veli-Matti Kosma	Biobank of Easte	rn Finland / University of Eastern Finland / Northern Savo Hospital District,	
1074	Kuopio, Finland			
1075	Teijo Kuopio	Central Finland I	Biobank / University of Jyväskylä / Central Finland Health Care District,	
1076	Jyväskylä, Finland			
1077				
1078	FinnGen Teams			
1079	Administration			
1080	Anu Jalanko	Institute for Mole	ecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1081	Huei-Yi Shen	Institute for Mole	ecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1082	Risto Kajanne	Institute for Mole	ecular Medicine Finland, HiLIFE, University of Helsinki, Finland	
1083	Mervi Aavikko	Institute for Mole	ecular Medicine Finland, HiLIFE, University of Helsinki, Finland	

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

Analysis Mitja Kurki Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States Juha Karjalainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States Pietro Della Briotta Parolo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Arto Lehisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Juha Mehtonen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Wei Zhou Broad Institute, Cambridge, MA, United States Masahiro Kanai Broad Institute, Cambridge, MA, United States Mutaamba Maasha Broad Institute, Cambridge, MA, United States **Clinical Endpoint Development** Hannele Laivuori Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Aki Havulinna Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Susanna Lemmelä Tuomo Kiiskinen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland L. Elisa Lahtela Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Communication Mari Kaunisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland **E-Science** Elina Kilpeläinen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Timo P. Sipilä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Georg Brein Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Oluwaseun Alexander Dada Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Awaisa Ghazal	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Anastasia Shcherban	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Constrains	
Genotyping	
Kati Donner	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Sample Collection Coo	ordination
Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
Helsinki	
Sample Logistics	
Päivi Laiho	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Tuuli Sistonen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Essi Kaiharju	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Markku Laukkanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Elina Järvensivu	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Sini Lähteenmäki	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Lotta Männikkö	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Regis Wong	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Registry Data Operati	ions
Hannele Mattsson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Sami Koskelainen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Tero Hiekkalinna	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
Teemu Paajanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

**Sequencing Informatics** Priit Palta Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Kalle Pärn Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Shuang Luo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Vishal Sinha Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland **Trajectory** Tarja Laitinen Pirkanmaa Hospital District, Tampere, Finland Mary Pat Reeve Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Harri Siirtola University of Tampere, Tampere, Finland Javier Gracia-Tabuenca University of Tampere, Tampere, Finland Mika Helminen University of Tampere, Tampere, Finland Tiina Luukkaala University of Tampere, Tampere, Finland Iida Vähätalo University of Tampere, Tampere, Finland **Data protection officer** Tero Jyrhämä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland FinBB - Finnish biobank cooperative Marco Hautalahti Laura Mustaniemi Mirkka Koivusalo Sarah Smith Tom Southerington **Declaration of Interests** The authors declare no competing interests.

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

Ethics statement Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20). The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018 71, BB2019 7, BB2019 8, BB2019 26, BB2020 1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland\_2017\_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

The FINRISK data used for the study were obtained from THL Biobank with application number BB2015 55.1 and UKBB data using the UK Biobank Resource with application number 22627. The study was approved by the Estonian Committee on Bioethics and Human Research (approval number 1.1-12/624). Figures and tables Figure 1: GWAS results for coronary atherosclerosis in FinnGen. Total number of independent genome-wide significant associations (GWS; p <  $5 \times 10^{-8}$ ) is 38, the lead variant in each marked with diamonds. Four novel associations for CVD- related phenotypes are highlighted with ±750 Mb around the lead variant in the region as red and the lead variant marked with red diamond......10 Figure 2: Phenome-wide association study (PheWAS) results for rs534125149. Total number of tested endpoints is 2 861 (A complete list of endpoints analyzed and their definitions is available at https://www.finngen.fi/en/researchers/clinical-endpoints). The dashed line represents the phenomewide significance threshold, multiple testing corrected by the number of endpoints = 0.05/2861 = Figure 3: Comparison of the effects (OR) of rs534125149 and rs201988637 for 14 endpoints with p-value < 1.75×10-5 (PWS) for rs534125149. 95% confidence intervals represented as grey lines.14 Figure 4: Cumulative incidence plots for myocardial infarction. Red line represents carriers (homoor heterozygous) for either rs534125149 or rs201988637, and blue line represent non-carriers. Dashed lines represent 95%- confidence intervals. Figure 5: Results for pulse pressure association across all cohorts with splice acceptor variant